Scarica l'app Stockscreener
20.45
1.02%
0.05
Precedente Chiudi:
$20.50
Aprire:
$20.71
Volume 24 ore:
2,822
Relative Volume:
0.03
Capitalizzazione di mercato:
$1.11B
Reddito:
-
Utile/perdita netta:
$-123.41M
Rapporto P/E:
-9.565
EPS:
-2.138
Flusso di cassa netto:
$-106.93M
1 W Prestazione:
+0.78%
1M Prestazione:
-8.52%
6M Prestazione:
+0.63%
1 anno Prestazione:
+33.44%
Intervallo 1D:
$20.30
$20.96
Intervallo di 1 settimana:
$18.81
$21.85
Portata 52W:
$15.37
$33.00
Pharvaris Nv Stock (PHVS) Company Profile
Confronta PHVS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| PHVS | 20.34 | 1.11B | 0 | -123.41M | -106.93M | -2.138 |
| VRTX | 446.50 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 740.39 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 592.20 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.97 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.80 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-09-25 | Iniziato | Wedbush | Outperform |
| 2023-08-15 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-05 | Iniziato | Bryan Garnier | Buy |
| 2022-09-13 | Ripresa | JMP Securities | Mkt Outperform |
| 2022-08-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-22 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-05-25 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-03-02 | Iniziato | BofA Securities | Neutral |
| 2021-03-02 | Iniziato | Morgan Stanley | Overweight |
| 2021-03-02 | Iniziato | Oppenheimer | Outperform |
| 2021-03-02 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Pharvaris Nv Borsa (PHVS) Ultime notizie
(PHVS) Long Term Investment Analysis - Stock Traders Daily
Pharvaris Reports 93% HAE Attack Reduction in Trial Data, Plans Phase 3 Study | PHVS Stock News - StockTitan
Pharvaris to Present HAE Treatment Progress at Guggenheim Healthcare Conference | PHVS Stock News - StockTitan
Trend Tracker for (PHVS) - Stock Traders Daily
Axonis Therapeutics Announces $115 Million Series A Financing - Financial Times
Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting - StockTitan
(PHVS) Proactive Strategies - Stock Traders Daily
Pharvaris (PHVS) Shares Cross Above 200 DMA - Nasdaq
PHVSPharvaris N.V. Ordinary Shares Latest Stock News & Market Updates - StockTitan
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at ... - The Hastings Tribune
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings - StockTitan
Pharvaris to Host Virtual Investor Event on October 23, 2024 - StockTitan
(PHVS) Investment Report - Stock Traders Daily
Pharvaris (NASDAQ:PHVS) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Pharvaris (NASDAQ:PHVS) Shares Gap DownShould You Sell? - MarketBeat
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at - The Bakersfield Californian
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop - StockTitan
Novo Holdings A S Buys 556,970 Shares of Pharvaris (NASDAQ:PHVS) - MarketBeat
Pharvaris N.V.'s SWOT analysis: promising HAE drug boosts stock outlook - Investing.com India
Pharvaris CBO Resigns, Team Absorbs Duties - TipRanks
(PHVS) Technical Data - Stock Traders Daily
Hereditary Angioedema Therapeutics Global Market Report Explores 2024: Size Forecast and Growth Prospects 2033 - WhaTech
Pharvaris (NASDAQ:PHVS) Shares Gap Down to $21.09 - MarketBeat
EQS-Adhoc: BRAIN Biotech AG concludes royalty monetization deal for up to EUR 128.88 million on investigational pharma compound deucrictibant with Royalty Pharma - sharewise
Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Paradise, NV – Injuries Reported in Vehicle Accident on I-215 W near Las Vegas Blvd Onramp - Local Accident Reports
Las Vegas, NV – Accident on I-215 E near Windmill Ln Results in Injuries - Local Accident Reports
North Las Vegas Man Charged in Fatal Hit-and-Run After Allegedly Fleeing Accident Scene - Hoodline
Paradise, NV – Vehicle Accident at I-215 E and Las Vegas Blvd - Local Accident Reports
Las Vegas, NV – Vehicle Accident at CC215 S and W Sunset Rd Causes Injuries - Local Accident Reports
Highway reopens outside Las Vegas after crash, fire in semi hauling lithium batteries - KRNV
Road closures persist after trucks carrying wood and batteries collide - News3LV
Appeal over identifying invasive hornets in Jersey - BBC.com
Hwy 95 closes in Nye County after crash involving truck carrying lithium batteries - Audacy
1 person transported to hospital after Henderson crash involving bicyclist - Fox 5 Las Vegas
1 hospitalized in Henderson crash involving bicyclistKLAS - KLAS - 8 News Now
Oregon man dies northwest of Las Vegas Valley, state police say - Fox 5 Las Vegas
1 person taken to hospital after crash involving car, bicyclist in Henderson - News3LV
Rep. Steven Horsford releases updated campaign ad after LVPPA concerns - KTNV 13 Action News Las Vegas
Silver Springs man killed in crash on U.S. 50A & 6th Street in Fernley - KTVN
Las Vegas, NV – Collision at CC215 S & W Flamingo Rd Results in Injuries - Local Accident Reports
Pharvaris (NASDAQ:PHVS) Shares Gap Up After Analyst Upgrade - MarketBeat
Pharvaris stock outlook strengthened with price target increase, Outperform rating reiterated by Oppenheimer - Investing.com UK
(PHVS) Technical Pivots with Risk Controls - Stock Traders Daily
Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and ... - The Bakersfield Californian
Pharvaris Provides Business Update and Expands Development Program for Deucrictibant - StockTitan
Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024 - StockTitan
Pharvaris Presents Data at the Bradykinin Symposium 2024 - StockTitan
Pharvaris to Present at SVB Securities Global Biopharma Conference - Yahoo Finance UK
Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium - Yahoo Finance UK
Pharvaris (NASDAQ:PHVS) Shares Gap Down to $19.08 - MarketBeat
Pharvaris Nv Azioni (PHVS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.42%
0.16%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):